InflaRx IFRX
NASDAQ IFRX
$1.53 -0.02 (-1.29%)
At close: Oct 22, 2026 · 4:00 PM EDT

InflaRx (IFRX) Accumulated Expenses (2020 - 2021)

Updated

InflaRx's Accumulated Expenses was $9.31 billion in Q4 2025, up 25.8% from $7.4 billion a year earlier.

Analysis

InflaRx (IFRX) Accumulated Expenses (2020 - 2021) Analysis & Trends

At the end of FY2025, Accumulated Expenses at InflaRx came in at $9.04 billion, up 22.1% from FY2024.

  • In earlier years, Accumulated Expenses was $7.4 billion in FY2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,165.22 Bn 1,133.81 Bn 19.71 Bn
2 Johnson & Johnson 646.28 Bn 566.14 Bn 17.30 Bn
3 AbbVie 503.17 Bn 476.28 Bn 12.70 Bn
4 Merck 365.23 Bn 319.60 Bn 12.21 Bn
5 Novartis Ag 302.66 Bn 266.65 Bn 11.24 Bn
6 Astrazeneca 267.39 Bn 241.08 Bn 12.86 Bn
7 Amgen 241.61 Bn 197.01 Bn 7.24 Bn
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn
9 Pfizer 172.91 Bn 119.55 Bn 10.94 Bn
10 InflaRx 103.29 Mn -230.33 Mn 2.74 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2021 6.71 Mn
Dec 31, 2020 10.18 Mn
API Access

InflaRx Accumulated Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=accumulated-expenses&ticker=IFRX&period=max&api_key=YOUR_API_KEY